
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with …
May 29, 2024 · WTX-124 is a half-life extended, masked cytokine (INDUKINE molecule) rationally engineered to release wild type IL-2 in tumors. We previously reported that WTX-124 is …
Discovery of a Conditionally Activated IL-2 that Promotes
May 3, 2022 · Here, we describe the design and characterization of a conditionally activated IL-2 prodrug, WTX-124, that takes advantage of the dysregulated protease milieu of tumors.
• Our work shows that WTX-124, a pro-drug containing wild-type IL-2, is selectively processed and activated in tumors and is efficacious in murine models, even in the presence of regulatory …
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 ...
4 days ago · WTX-124: a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with …
Werewolf Therapeutics Presents Preliminary Monotherapy Data …
Nov 3, 2023 · Study WTX-124x2101 is evaluating WTX-124 as a monotherapy and in combination with pembrolizumab in patients with immunotherapy sensitive advanced or metastatic solid …
Werewolf Therapeutics Updates on Clinical Trials for WTX-124
4 days ago · Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non …
Discovery of a Conditionally Activated IL-2 that Promotes …
May 3, 2022 · WTX-124, an IL-2 containing INDUKINE protein, was designed to enhance the clinical profile of rhIL-2 treatment by facilitating less frequent systemic delivery, increasing the …
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 ...
WTX-124 exhibits approximately dose-proportional PK with very low levels of active IL-2 (<1% of prodrug). Tumor biopsies are being analyzed for changes in the frequency and functionality of …
Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is …
Jun 15, 2022 · To address these limitations, we designed WTX-124, an IL-2 pro-drug (IL-2 INDUKINE™ protein) that takes advantage of dysregulated protease activity in the tumor …
WTX-124 by Werewolf Therapeutics for Adenocarcinoma Of The ...
The company investigating WTX-124, a conditionally activated interleukin-2 (IL-2) based drug to treat multiple tumor types and WTX-330 and WTX-613 drugs administered as monotherapies …